Estrogen Receptor-Alpha, Breast Cancer Patients And Tamoxifen Response
Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen receptor (ER)-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute. Approximately 50% of breast carcinomas are resistant to tamoxifen.
source : www.medicalnewstoday.com
Related News:
- New Research Confirms Skin Cancer Prevention One Of The Nation’s Best Health Investments
- Michael Douglas chooses toxic chemotherapy, radiation to battle throat cancer
- Scientists create new process to ‘program’ cancer cell death
- ‘Magic Mushrooms’ Possible Tx in End-Stage Cancer
- Paris Will Host The 14th International Thyroid Congress From September 11th To 16th, 2010
- Chemical In Widely Consumed Foods Linked To Skin Cancer
- CyberKnife Treatment For Prostate Cancer
- Novel nanotechnology collaboration leads to breakthrough in cancer research
- Drug Discovery Tools To Fight Cancer, Blindness To Be Discussed At UB Symposium
- Near Infrared Light May Open New Frontier In Fighting Cancer, Tay-Sachs
Details :
Submited at Friday, November 27th, 2009 at 7:00 am on Endocrinology by admin
Comment RSS 2.0 - leave a comment - trackback
Leave Comment Here...